Abstract: Rapamycin derivatives have interesting effects in the treatment of solid tumours, optionally in combination with a chemotherapeutic agent.

Abstract: A chewing gum is disclosed with immunity boosting properties to ward off illness and promote favorable health. The chewing gum begins with a gum base, to which various medicinal elements are added so that they can be released during mastication of the gum. The medicinal elements include zinc, Vitamin C, elderberry, astragalus, eleutherococcus, and echinacea.

Abstract: A method of treating a warm-blooded animal, especially a human, having a proliferative disease or acute or chronic transplant rejection comprising administering to the animal a combination which comprises (a) N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and (b) a chemotherapeutic agent selected from antineoplastic agents, especially as defined herein, and agents effective in treating acute or chronic transplant rejection; a combination comprising (a) and (b) as defined above and optionally at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular for the delay of progression or treatment of a proliferative disease, especially a solid tumor disease.

Abstract: Rapamycin derivatives have interesting effects in the treatment of solid tumours, optionally in combination with a chemotherapeutic agent.

Abstract: Rapamycin derivatives have interesting effects in the treatment of solid tumours, optionally in combination with a chemotherapeutic agent.

Abstract: The present invention is an energy drink that included both creatine and caffeine, which provides superior energy, concentration and performance over other energy beverages/liquids. The invention can include other vitamins and beneficial additives, but is intended to be unflavored and unsweetened.

Abstract: Methods and associated structures of forming microelectronic devices are described. Those methods may include forming a magnetic material on a substrate, wherein the magnetic material comprises rhenium, cobalt, iron and phosphorus, and annealing the magnetic material at a temperature below about 330 degrees Celsius, wherein the coercivity of the annealed magnetic material is below about 1 Oersted.

Abstract: The invention relates to the treatment of a proliferative disease, especially according to certain treatment regimens, with an epothilone, especially with epothilone A and more preferably epothilone B; as well as to the treatment of certain cancers with such an epothilone.

Abstract: Provided are biomarkers for determining the sensitivity of proliferative diseases such as cancer to therapeutic agents, in particular mTOR inhibitors in combination with a cytotoxic agent, in particular a cytotoxic agent which damages or affects the integrity of DNA.

Abstract: The present invention relates to a combination comprising N-{5-[4-(4-methyl-piperazino-methyl) -benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and an epothiione derivative; pharmaceutical composition comprising said combination; method of treatment comprising said combination; and commercial packages comprising said combination.

Abstract: A method of treating a warm-blooded animal, especially a human, having a proliferative disease or acute or chronic transplant rejection comprising administering to the animal a combination which comprises (a) N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and (b) a chemotherapeutic agent selected from antineoplastic agents, especially as defined herein, and agents effective in treating acute or chronic transplant rejection; a combination comprising (a) and (b) as defined above and optionally at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular for the delay of progression or treatment of a proliferative disease, especially a solid tumor disease.

Abstract: Methods and associated structures of forming microelectronic devices are described. Those methods may include forming a magnetic material on a substrate, wherein the magnetic material comprises rhenium, cobalt, iron and phosphorus, and annealing the magnetic material at a temperature below about 330 degrees Celsius, wherein the coercivity of the annealed magnetic material is below about 1 Oersted.

Abstract: Use of a combination of an mTOR inhibitor and an antifolate compound.

Abstract: The present invention is an apparatus and method for applying a tourniquet device to an injured appendage requiring only one hand comprising the steps of providing a releasable cable tie having an elongate band portion with regularly spaced grooves or projections on a first surface and a relatively smooth second surface, and a shroud member disposed at a proximal end of said elongate band portion adapted to receive the distal end of the band portion and having a releasable groove or projection engaging element incorporated therein, forming a loop with said elongate band member such that the relatively smooth surface is facing radially inward and the regularly spaced grooves open radially outward, maneuvering the loop about the injured appendage, inserting the distal end of the elongate band into the shroud member such that the groove or projection engaging member is adjacent the grooves or projections, pulling the distal end of the elongate band through the shroud member until the requisite restriction of blo

Abstract: Disclosed is a method for determining the sensitivity of a proliferate disease in a subject to treatment with an mTOR inhibitor, comprising determining the level of expression and/or phosphorylation state of S6 in a sample derived from the subject, as well as related methods of treatment and uses.

Abstract: A method for the treatment of pain, in particular antinociceptive or anti-allodynic treatment of pain, in a patient in need of such treatment, e.g. a patient with osteoporosis or osteopenia, a tumour patient or a patient suffering from an inflammatory disease, which comprises administering an effective amount of a bisphosphonate, e.g.

Abstract: Provided are biomarkers for determining the sensitivity of proliferative diseases such as cancer to therapeutic agents, in particular mTOR inhibitors in combination with a cytotoxic agent, in particular a cytotoxic agent which damages or affects the integrity of DNA.

Abstract: An insulating layer (5) and a conductive seed layer (6) are applied to a substrate (1) in a simple process. A photo resist with palladium chloride are provided in a bath for electrophoretic deposition onto the substrate. The photo resist is an insulator and the palladium chloride is a catalyst. The layer is heated with UV to cure it. The layer is plasma etched to expose more of the palladium chloride, which acts as a catalyst for electrodes plating of the conductive seed layer. A thicker conductive layer (7) is then electroplated onto the seed layer. These steps may be repeated for successive insulating and/or conductive layers.

Abstract: A secure file service includes a cryptographic processor (302, 602) and a secure file system (301, 601). The cryptographic processor is comprised of a trusted microprocessor and a trusted operating system executing on the trusted cryptographic processor. The cryptographic processor includes hardware and software for accessing at least one classified data file from the secure file system, decrypting the classified data file, and serving the classified data file in decrypted form to a secure user processor (402, 502, 702) that has requested the file. The secure file system can be either a single-level secure file system (301) or a multi-level secure file system (601).

Abstract: Mobile PDA computer system (300) includes a secure user processor (302), a non-secure user processor (306), a cryptographic engine (304), and a shared human/machine interface (HMI) (308). The secure user processor (302) can be comprised of a first trusted microprocessor and a first trusted operating system executing on the first trusted microprocessor. The non-secure user processor (306) can be comprised of a second non-trusted microprocessor and a second non-trusted operating system executing on the second non-trusted microprocessor. A cryptographic engine (304) can be comprised of a third trusted cryptographic processor and a third trusted operating system executing on the third trusted cryptographic processor. The cryptographic engine can be configured for encrypting and decrypting data. A first data communication link (303) communicates data between the secure user processor and the cryptographic engine.